AI drug discovery is entering a new phase, due to a strategic partnership between Bristol Myers Squibb and Takeda Pharmaceuticals. The two companies are joining forces with other major players to speed up the development of new medicines using artificial intelligence.
This collaboration isn’t just about technology it’s about transforming how the pharmaceutical industry approaches drug development. Alongside Astex Pharmaceuticals, Bristol Myers and Takeda are contributing proprietary data to train OpenFold3, a powerful AI model designed to predict how proteins interact with small molecules. These interactions are key to identifying potential drug candidates.
The initiative is part of a broader consortium that includes AbbVie, Johnson & Johnson, and Columbia University’s AlQuraishi Lab. The project is being coordinated by Apheris, a Germany-based life sciences company that specializes in secure data collaboration.
What makes this effort stand out is the way data is being shared. Instead of moving sensitive information between companies, the consortium is using a federated data-sharing model. This approach allows each organization to keep its data securely in place while still contributing to the AI’s training. Apheris’ platform makes this possible by connecting datasets without compromising privacy.
The data being used includes thousands of experimentally determined protein small molecule structures. These structures are essential for understanding how drugs behave in the human body. By pooling this information, the consortium hopes to improve OpenFold3’s accuracy and make it a more effective tool for drug discovery.
“This collaboration allows us to build predictive models that no single company could develop on its own,” said Payal Sheth, Vice President of Discovery Biotherapeutics at Bristol Myers Squibb. “It’s a powerful example of how working together can lead to faster innovation and better outcomes for patients.”
Hans Bitter, Head of Computational Sciences at Takeda, shared a similar view. “This project fits perfectly with our goal of embedding AI into every part of our work. It also shows how pharma companies can unite to achieve more than we ever could individually.”
OpenFold3 is the flagship project of the AI Structural Biology Network. This network brings together industry leaders and academic researchers to solve complex biological problems using artificial intelligence. The collaboration with Columbia University adds scientific depth and credibility to the initiative.
The use of AI in drug development is no longer a futuristic concept—it’s happening now. Traditional drug discovery methods are slow and expensive. They often take years and cost billions of dollars. AI models like OpenFold3 can analyze massive amounts of biological data quickly, helping researchers identify promising compounds in a fraction of the time.
This partnership also reflects a broader shift in the pharmaceutical industry. Companies are increasingly open to collaboration, especially when it comes to using advanced technologies. By working together, they can tackle challenges that would be difficult to solve alone.
The federated data-sharing model is a game-changer. It allows companies to collaborate without giving up control of their data. This approach could become a blueprint for future partnerships in healthcare and beyond.
If OpenFold3 delivers on its promise, the impact could be significant. Faster drug discovery means quicker access to treatments, more personalized medicine, and a more efficient development process. It could also open the door to new collaborations that use AI to address other pressing healthcare issues.
As artificial intelligence continues to evolve, projects like this one show what’s possible when innovation meets cooperation. Bristol Myers, Takeda, and their partners are setting a new standard for how the industry can work together to improve lives.
This isn’t just a technical achievement it’s a shift in mindset. It’s about recognizing that the future of medicine depends not only on smart algorithms but also on smart partnerships. And with OpenFold3, the pharmaceutical industry is taking a bold step in the right direction.
